A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
BioXcel Therapeutics Inc
BioXcel Therapeutics Inc
Hutchmed
PharmaMar
Hoffmann-La Roche
Imperial College London
Memorial Sloan Kettering Cancer Center
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Medical University Innsbruck
Duke University
Peking Union Medical College Hospital
Tarveda Therapeutics
University of Iowa
Ipsen
Arbutus Biopharma Corporation
Molecular Insight Pharmaceuticals, Inc.